<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05019378</url>
  </required_header>
  <id_info>
    <org_study_id>Zhongnanzxx</org_study_id>
    <nct_id>NCT05019378</nct_id>
  </id_info>
  <brief_title>SVF Therapy for Human Knee Osteoarthritis</brief_title>
  <official_title>Evaluation of the Autologous Stromal Vascular Fraction Therapy for Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to asses the safety and efficacy of SVF for treatment of knee&#xD;
      osteoarthritis, and establish a novel method to provide 3D MRI imaging for human knee&#xD;
      cartilage to qualitatively and quantitatively evaluate cartilage regeneration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participants voluntarily provided written informed consent to participate in the study.&#xD;
      The two knees of each patient were randomly assigned to autologous SVF treatment group or&#xD;
      non-treatment control group. The patients were evaluated every 4 weeks for safety and&#xD;
      efficacy of autologous SVF therapy for 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2016</start_date>
  <completion_date type="Actual">January 28, 2019</completion_date>
  <primary_completion_date type="Actual">August 23, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiologic evaluation of knee articular cartilage Volume</measure>
    <time_frame>Change from Baseline articular cartilage Volume at 12 weeks</time_frame>
    <description>The Volume (cubic millimeter) of knee articular cartilage are measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiologic evaluation of knee articular cartilage Volume</measure>
    <time_frame>Change from Baseline articular cartilage Volume at 24 weeks</time_frame>
    <description>The Volume (cubic millimeter) of knee articular cartilage are measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiologic evaluation of knee articular cartilage Area</measure>
    <time_frame>Change from Baseline articular cartilage Area at 12 weeks</time_frame>
    <description>The Area (square millimeter) of knee articular cartilage are measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiologic evaluation of knee articular cartilage Area</measure>
    <time_frame>Change from Baseline articular cartilage Area at 24 weeks</time_frame>
    <description>The Area (square millimeter) of knee articular cartilage are measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiologic evaluation of knee articular cartilage Thickness</measure>
    <time_frame>Change from Baseline articular cartilage Thickness at 12 weeks</time_frame>
    <description>The Thickness (millimeter) of knee articular cartilage are measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiologic evaluation of knee articular cartilage Thickness</measure>
    <time_frame>Change from Baseline articular cartilage Thickness at 24 weeks</time_frame>
    <description>The Thickness (millimeter) of knee articular cartilage are measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee pain evaluation and functional evaluation (the Western Ontario and McMaster University arthritis index [WOMAC])</measure>
    <time_frame>Change from Baseline WOMAC arthritis index score at 12 weeks.</time_frame>
    <description>Knee pain and functional mobility were assessed using WOMAC arthritis index patient questionnaire including 24 parameters for pain, stiffness and physical function. The values ranging from 0 (minimum) to 240 (maximum) and the lower scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee pain evaluation and functional evaluation (the Western Ontario and McMaster University arthritis index [WOMAC])</measure>
    <time_frame>Change from Baseline WOMAC arthritis index score at 24 weeks.</time_frame>
    <description>Knee pain and functional mobility were assessed using WOMAC arthritis index patient questionnaire including 24 parameters for pain, stiffness and physical function. The values ranging from 0 (minimum) to 240 (maximum) and the lower scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee pain evaluation and functional evaluation (The Lysholm Knee Scoring Scale)</measure>
    <time_frame>Change from Baseline Lysholm Knee Scale score at 12 weeks.</time_frame>
    <description>The Lysholm Knee Scoring Scale questionnaire has been designed to evaluate how patients' knee pain has affected their ability to manage everyday life. The values ranging from 0 (minimum) to 100 (maximum) and the higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee pain evaluation and functional evaluation (The Lysholm Knee Scale)</measure>
    <time_frame>Change from Baseline Lysholm Knee Scale score at 24 weeks.</time_frame>
    <description>The Lysholm Knee Scoring Scale questionnaire has been designed to evaluate how patients' knee pain has affected their ability to manage everyday life. The values ranging from 0 (minimum) to 100 (maximum) and the higher scores mean a better outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>autologous SVF treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three milliliter of cell suspension injection containing 1.0E8 SVF cells into the knee joint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SVF treatment</intervention_name>
    <description>autologous SVF (10E8 cells)</description>
    <arm_group_label>autologous SVF treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Knee Osteoarthritis&#xD;
&#xD;
          -  Articular cartilage defect grades I/II of both knee&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  autoimmune or inflammatory arthritis&#xD;
&#xD;
          -  serious medical disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Xiao Zheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Cai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>437200</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cartilage Defect</keyword>
  <keyword>Cartilage Regeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected IPD, all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

